세계의 유방암 스크리닝 검사 시장 보고서(2025년)
Breast Cancer Screening Test Global Market Report 2025
상품코드 : 1760494
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

유방암 스크리닝 검사 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 8.3%의 연평균 성장률(CAGR)로 34억 6,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 유방암 발병률 증가, 정부 이니셔티브 강화, 의료비 지출 증가, 이동 검진 유닛 확대, 여성 인구 증가 등과 관련이 있습니다. 이 기간 동안 예상되는 주요 동향으로는 영상 진단 기술 발전, 비침습적 검진 기술의 부상, 유전자 검사의 발전, 유전체 검사의 혁신, 모바일 검진 솔루션의 개발 등이 있습니다.

유방암 발병률의 증가는 유방암 선별검사 시장의 성장을 촉진할 것으로 예상됩니다. 유방암은 유방 조직에서 세포의 비정상적이고 통제할 수 없는 증식을 동반하며, 종양으로 발전하여 다른 신체 부위로 전이될 수 있습니다. 유방암 환자의 증가는 전 세계 인구의 고령화에 기인하며, 나이가 들수록 발병 위험이 크게 증가하기 때문입니다. 유방암 검진은 유방암을 조기에 발견하고, 치료 성적을 개선하고, 사망률을 낮추기 위해 필수적입니다. 예를 들어, 미국 비영리단체 Breastcancer.org는 2025년 3월에 비침윤성 유관암(DCIS) 59,080건과 함께 약 31만 6,950명의 여성이 2025년에 침윤성 유방암 진단을 받을 것으로 예측했습니다. 또한, 2024년 12월 캐나다 공중보건국은 2022년 캐나다에서 약 28,600명의 여성이 유방암 진단을 받고 5,500명이 사망할 것으로 예상했습니다. 결과적으로 유방암 유병률의 증가는 유방암 스크리닝 검사 시장의 확대에 기여하고 있습니다.

유방암 스크리닝 검사 분야의 주요 기업들은 접근성 향상, 조기 발견 증가, 의료 서비스가 부족한 지역 및 오지 지역으로의 서비스 확대를 위해 이동형 검진 유닛과 같은 최첨단 솔루션 개발에 우선순위를 두고 있습니다. 이러한 이동식 검진 유닛은 유방촬영술과 같은 영상 진단 기술을 갖춘 이동식 시설로, 의료 접근성이 부족한 지역에서 현장 유방암 검진을 제공하도록 설계되어 있습니다. 예를 들어, 2024년 9월 인도의 제약회사 Granules India Ltd.는 소외된 지역의 유방암 검진을 촉진하기 위해 Breast Health Express를 도입했습니다. 첨단 유방 촬영 및 초음파 시스템을 갖춘 이 장비는 이동 중에도 양질의 검진을 받을 수 있습니다. 이 이니셔티브는 농촌 지역과 의료 서비스가 부족한 지역에 조기 발견 서비스를 제공하여 해당 지역 여성들이 중요한 의료 서비스를 이용할 수 있도록 하는 것을 목표로 하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

A breast cancer screening test is a medical procedure or diagnostic method designed to detect breast cancer at an early stage, often before any symptoms develop. The main objective of screening is to discover cancer when it is most treatable, thereby potentially lowering mortality rates and enhancing patient outcomes. Early diagnosis through breast cancer screening enables timely treatment and leads to a more favorable prognosis.

The primary types of diagnostic tests used in breast cancer screening include blood marker tests, imaging tests, genetic tests, and immunohistochemistry tests. Blood marker tests identify and quantify specific substances in the blood to support disease detection, monitoring, or risk evaluation. Different levels of risk-high-risk, moderate-risk, and average-risk populations-are considered, and the tests are utilized by various end users, including hospitals, diagnostic centers, cancer institutes, and research laboratories.

The breast cancer screening tests market research report is one of a series of new reports from The Business Research Company that provides breast cancer screening tests market statistics, including the breast cancer screening tests industry's global market size, regional shares, competitors with the breast cancer screening tests market share, detailed breast cancer screening tests market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer screening tests market. This breast cancer screening tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The breast cancer screening test market size has grown strongly in recent years. It will grow from $2.31 billion in 2024 to $2.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be credited to enhanced reimbursement policies, a stronger emphasis on preventive healthcare, increased health awareness, greater investment in research and development, and heightened awareness regarding early detection.

The breast cancer screening test market size is expected to see strong growth in the next few years. It will grow to $3.46 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The anticipated growth in the forecast period can be linked to the rising incidence of breast cancer, increased government initiatives, growing healthcare spending, the expansion of mobile screening units, and a rise in the female population. Key trends expected during this period include technological advancements in imaging, the emergence of non-invasive screening techniques, progress in genetic testing, innovations in genomic testing, and the development of mobile screening solutions.

The increasing incidence of breast cancer is anticipated to drive the growth of the breast cancer screening test market. Breast cancer involves the abnormal and uncontrolled growth of cells in breast tissue, which can develop into a tumor and potentially spread to other body parts. The rise in breast cancer cases is attributed to the aging global population, as older age significantly raises the risk of developing the disease, and longer life expectancies mean a greater number of individuals are at risk. Screening tests for breast cancer are essential for identifying the disease in its early stages, thereby improving treatment outcomes and lowering mortality rates. For example, in March 2025, Breastcancer.org, a nonprofit organization based in the US, projected that approximately 316,950 women would be diagnosed with invasive breast cancer in 2025, along with 59,080 new cases of non-invasive ductal carcinoma in situ (DCIS). Additionally, in December 2024, the Public Health Agency of Canada reported that an estimated 28,600 women in Canada were expected to be diagnosed with breast cancer in 2022, with 5,500 fatalities anticipated. As a result, the rising prevalence of breast cancer is contributing to the expansion of the breast cancer screening test market.

Leading companies in the breast cancer screening test sector are prioritizing the development of cutting-edge solutions such as mobile screening units to improve accessibility, increase early detection, and extend services to underserved or remote regions. These mobile units are transportable facilities equipped with diagnostic imaging technologies like mammography, designed to deliver on-site breast cancer screening in areas lacking adequate healthcare access. For instance, in September 2024, Granules India Ltd., a pharmaceutical company based in India, introduced the Breast Health Express to promote breast cancer screening in disadvantaged communities. Outfitted with advanced mammography and ultrasound systems, the unit facilitates quality screenings while on the move. This initiative aims to bring early detection services to rural and underserved areas, helping to ensure access to critical healthcare for women in these regions.

In August 2024, Hitachi High-Tech Corporation, a Japan-based producer of electronic and electrical equipment, entered into a strategic alliance with Gencurix Inc. for an undisclosed amount. Through this collaboration, Hitachi seeks to utilize its knowledge in in vitro diagnostics and digital technologies to create accurate and efficient molecular diagnostics for cancer. Gencurix Inc., headquartered in South Korea, specializes in breast cancer testing solutions.

Major players in the breast cancer screening test market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH, Fujifilm Corporation, Koninklijke Philips NV, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Hologic Inc., Hitachi High-Tech Corporation, Exact Sciences Corporation, Natera Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, Provista Diagnostics Inc., POC Medical Systems Inc., Niramai Health Analytix Pvt. Ltd., Kheiron Medical Technologies Limited, UE LifeSciences Inc., Dxcover Limited.

North America was the largest region in the breast cancer screening test market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in breast cancer screening test report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the breast cancer screening test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The breast cancer screening test market consists of revenues earned by entities by providing services such as early detection, risk assessment, and tumor detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer screening test market also consists of sales of products including ultrasound equipment, screening software, and breast self-examination kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Screening Test Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer screening test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for breast cancer screening test ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The breast cancer screening test market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Subsegments

Table of Contents

1. Executive Summary

2. Breast Cancer Screening Test Market Characteristics

3. Breast Cancer Screening Test Market Trends And Strategies

4. Breast Cancer Screening Test Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Breast Cancer Screening Test Growth Analysis And Strategic Analysis Framework

6. Breast Cancer Screening Test Market Segmentation

7. Breast Cancer Screening Test Market Regional And Country Analysis

8. Asia-Pacific Breast Cancer Screening Test Market

9. China Breast Cancer Screening Test Market

10. India Breast Cancer Screening Test Market

11. Japan Breast Cancer Screening Test Market

12. Australia Breast Cancer Screening Test Market

13. Indonesia Breast Cancer Screening Test Market

14. South Korea Breast Cancer Screening Test Market

15. Western Europe Breast Cancer Screening Test Market

16. UK Breast Cancer Screening Test Market

17. Germany Breast Cancer Screening Test Market

18. France Breast Cancer Screening Test Market

19. Italy Breast Cancer Screening Test Market

20. Spain Breast Cancer Screening Test Market

21. Eastern Europe Breast Cancer Screening Test Market

22. Russia Breast Cancer Screening Test Market

23. North America Breast Cancer Screening Test Market

24. USA Breast Cancer Screening Test Market

25. Canada Breast Cancer Screening Test Market

26. South America Breast Cancer Screening Test Market

27. Brazil Breast Cancer Screening Test Market

28. Middle East Breast Cancer Screening Test Market

29. Africa Breast Cancer Screening Test Market

30. Breast Cancer Screening Test Market Competitive Landscape And Company Profiles

31. Breast Cancer Screening Test Market Other Major And Innovative Companies

32. Global Breast Cancer Screening Test Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Screening Test Market

34. Recent Developments In The Breast Cancer Screening Test Market

35. Breast Cancer Screening Test Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기